Cost-benefit analysis of thrombolytic therapy

Area of Science:

• Cardiology
• Health Economics

Background:

• Myocardial infarction (MI) management involves evaluating new treatments.
• Cost-benefit analysis is crucial for assessing therapeutic interventions.

Purpose of the Study:

• To conduct a cost-benefit analysis of thrombolytic therapy versus classical treatment for myocardial infarction patients.
• To evaluate the economic impact and patient outcomes over a one-year period.

Main Methods:

• A cohort of 162 myocardial infarction patients was studied.
• 62 patients received thrombolytic treatment, while 100 received classical therapy.
• Patients were followed for one year with cost-induced disease questionnaires.

Main Results:

• Thrombolysis incurred higher initial costs (£10,550 vs £8,998) and a 2-day longer hospital stay.
• However, thrombolysis reduced rehospitalization by 10.3 days.
• Monetary benefits became positive by year-end, with a cost-benefit ratio of approximately 0.7.

Conclusions:

• Thrombolytic therapy requires an investment of £150 per day of reduced rehospitalization.
• Despite higher upfront costs, thrombolysis yields substantial monetary benefits and improved outcomes within one year.
• The study supports the long-term economic viability of thrombolytic treatment for myocardial infarction.